AKT1 and melanoma: Thus, melanomas showing a loss of PTEN activity which do not respond to BRAFi-based targeted therapy, or which have developed resistance through the hyperactivation of the PI3K signalling pathway could benefit from RASSF1A expression through its direct inhibition of the PI3K/AKT anti-apoptotic signalling.